Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
100 hedge funds and large institutions have $106M invested in Endocyte, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 36 reducing their positions, and 21 closing their positions.
6% more capital invested
Capital invested by funds: $101M → $106M (+$5.7M)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% less funds holding
Funds holding: 101 → 100 (-1)
28% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 36
28% less call options, than puts
Call options by funds: $1.88M | Put options by funds: $2.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.59M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.51M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.76M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.01M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$958K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$4.16M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$1.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.34M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$1.32M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$815K |
ECYT Hedge Fund Activity: Q4 2014 in Review
100 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2014, worth a combined $106M — up 5.7% from $101M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ECYT positions and 21 closed out — a net gain of 1 holder — while 26 added to existing stakes and 36 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $2.59M. The largest seller was BB Biotech, exiting entirely with an estimated $4.16M sold.
- 100 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2014, down from 101 in Q3 2014.
- Funds reported $106M of Endocyte, Inc. Common Stock stock for Q4 2014, up 5.7% quarter-over-quarter.
- 22 funds opened new Endocyte, Inc. Common Stock positions in Q4 2014 and 21 closed out, a net change of +1 holder.
- The largest Endocyte, Inc. Common Stock buyer in Q4 2014 was Renaissance Technologies, an estimated $2.59M added.
- The largest Endocyte, Inc. Common Stock seller in Q4 2014 was BB Biotech, an estimated $4.16M sold.
Based on aggregated 13F filings for Q4 2014.